You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEK Inhibition

Showing 1 - 25 of 3,077
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma Trial in Leiden (Encorafenib + Binimetinib)

Recruiting
  • Melanoma Stage III
  • In-Transit Metastasis of Cutaneous Melanoma
  • Encorafenib + Binimetinib
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Mar 2, 2023

Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 14, 2022

Prostate Cancer Trial in Los Angeles (degarelix, enzalutamide, trametinib)

Active, not recruiting
  • Prostate Cancer
  • Los Angeles, California
    University of California, Los Angeles
Aug 25, 2022

Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

Recruiting
  • Metastatic Melanoma
  • BRAF Gene Mutation
  • Nilotinib 100mg
  • +5 more
  • Lexington, Kentucky
    Markey Cancer Center
Jul 22, 2022

Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma Trial (BRD4 Inhibitor PLX2853, Trametinib,

Not yet recruiting
  • Advanced Uveal Melanoma
  • +2 more
  • BRD4 Inhibitor PLX2853
  • +4 more
  • (no location specified)
Jan 9, 2023

Pancreatic Ductal Adenocarcinoma Trial in Miami (Trametinib, Ruxolitinib, Retifanlimab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Miami, Florida
    University of Miami
Jun 27, 2022

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma

Active, not recruiting
  • Melanoma
  • Dabrafenib and Trametinib
  • Buxtehude, Niedersachsen, Germany
  • +35 more
Aug 25, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Dabrafenib Mesylate
  • +2 more
  • Atlanta, Georgia
  • +6 more
Nov 30, 2022

Advanced BRAF Mutant Melanoma Trial in United States (Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally

Completed
  • Advanced BRAF Mutant Melanoma
  • Trametinib 2 mg daily
  • +2 more
  • Chicago, Illinois
  • +3 more
Jan 18, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +11 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Mar 22, 2022

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

Terminated
  • BRAF V600E Mutation Present
  • +7 more
  • Boston, Massachusetts
  • +1 more
Mar 9, 2022

Rectal Cancer Trial in Manchester (AZD6244, Cediranib (AZD2171))

Terminated
  • Rectal Cancer
  • Manchester, United Kingdom
    The Christie NHS Foundation Trust
Feb 11, 2021

Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial

Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +4 more
  • Dabrafenib Mesylate
  • +3 more
  • Philadelphia, Pennsylvania
    Perelman Center for Advanced Medicine
Dec 29, 2021

Solid Tumor, Colorectal Cancer Trial in Oxford (PF-02341066, PD-0325901, Binimetinib)

Completed
Has Results
  • Solid Tumor
  • Colorectal Cancer
  • Oxford, United Kingdom
    Oxford University Hospital NHS Trust
Jun 14, 2021

Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)

Recruiting
  • Anaplastic Thyroid Cancer
  • Leiden, Zuid-Holland, Netherlands
    Ellen Kapiteijn
Oct 5, 2023

Rosacea, Erythematotelangiectatic Trial in Albany (Trametinib)

Recruiting
  • Rosacea, Erythematotelangiectatic
  • Albany, New York
    Samuel S. Stratton VA Medical Center
Nov 9, 2022

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Healthy Trial in Neu-Ulm (ATR-002, Placebo, Repaglinide)

Recruiting
  • Healthy
  • Neu-Ulm, Germany
    Atriva study site
Sep 22, 2022

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • New York, New York
  • +2 more
Jun 28, 2022

Metastatic Melanoma Trial in Netherlands (drug, device, procedure)

Terminated
  • Metastatic Melanoma
  • Vemurafenib plus cobimetinib
  • +3 more
  • Amsterdam, Netherlands
  • +9 more
Nov 24, 2022

Low-Grade Gliomas, Malignant Tumors, Brain, Soft Tissue Tumors Trial in United States (MEK162)

Active, not recruiting
  • Low-Grade Gliomas
  • +2 more
  • Birmingham, Alabama
  • +14 more
Jan 25, 2023

Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) Trial in United States (Mirdametinib (PD-0325901) oral capsule or

Active, not recruiting
  • Plexiform Neurofibroma
  • Neurofibromatosis Type 1 (NF1)
  • Mirdametinib (PD-0325901) oral capsule or dispersible tablet
  • Birmingham, Alabama
  • +49 more
Nov 17, 2022

Melanoma (Skin) Trial in Dijon, Thionville, Vandœuvre-lès-Nancy (Blood sampling)

Active, not recruiting
  • Melanoma (Skin)
  • Blood sampling
  • Dijon, France
  • +3 more
Mar 29, 2022

Metastatic Thyroid Cancer Trial in Essen (Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2)

Recruiting
  • Metastatic Thyroid Cancer
  • Trametinib 2 MG [Mekinist]
  • Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
  • Essen, Northrhine-Westphalia, Germany
    Manuel M. Weber
May 17, 2022